UA138724U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of endothelin, C-terminal propeptide type I collagen (CISR), C-reactive protein (PSP), homocysteine and homozygous carrier level. 10 ng / ml, SISR <102 ng / ml, PSA> 6 mg / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

Useful model The method of predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include radiography, examination of a biopsy of the synovial membrane, synovial fluid, a biopsy of cartilage (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the nitric oxide synthase gene (eMO5 1786C), the content of endothelin, the C-terminal propeptide of collagen is determined in the patient's blood serum | type (SISR), C-reactive protein (SRP), homocysteine and homozygous carrier 786-SS, endothelin levels 210 ng/ml, SISR "102 ng/ml, SRP "6 mg/l, homocysteine 220 μmol/l predict the development osteoarthritis

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the eMmo5 1786C gene polymorphism is determined, the endothelin content is determined by the immunoenzymatic method,

SISR, SRP, homocysteine. With homozygous carrier 786-SS and endothelin levels of 210 ng/ml,

SISR "102 ng/ml, SRP "6 mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method

Patient B., 68 years old, was hospitalized for pain in the left hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. The eMO5 1786C gene polymorphism and the content of endothelin, SISR, SRP, and homocysteine were determined in the blood serum using the immunoenzymatic method. A homozygous carrier of 786-SS was established, endothelin levels - 24 ng/ml, SISR - 78 ng/ml, SRP - 19 mg/l, homocysteine - 35 μmol/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Zo

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (EEMO5 1786C), the content of endothelin, the C-terminal propeptide of type I collagen is additionally determined in the patient's blood serum (SISR), C-reactive protein (CRP), homocysteine and with homozygous carrier 786-SS, levels of endothelin "10 ng/ml, SISR "102 ng/ml, SRP "6b mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.